Eligible patients will have histologically/cytologically confirmed EGFR-mutant NSCLC, and MET amplification disease by central fluorescence in situ hybridization (FISH), central immunohistochemistry (IHC), or local next generation sequencing (NGS—retrospectively confirmed by central FISH/IHC). Here, EGFR is linked to non-small cell lung carcinoma.